WHAT: SNM Symposium on Multimodality Cardiovascular Molecular Imaging
This two-day symposium focuses on advances in stem cell therapy, leading-edge research in imaging technology and targeted imaging of the cardiovascular system, including imaging of cardiovascular receptors, vascular biology, myocardial metabolism and myocardial repair.
SNM and the International Partnership for Critical Markers of Disease will host a satellite meeting devoted to FDA requirements for manufacturing PET radiopharmaceuticals the evening of Friday, May 1. This meeting will take place immediately following the conclusion of the Multimodality Cardiovascular Molecular Imaging Symposium.
Registration is free for members of the press and freelancers with a letter of assignment. Advance and on-site phone interviews can also be arranged with presenters for members of the press who wish to cover the symposium remotely.
WHEN: Thursday, April 30Friday, May 1, 2009
WHERE: Natcher Auditorium, National Institutes of Health, Bethesda, Md.
WHY: The symposium brings together individuals from multiple scientific disciplinesincluding medicine, chemistry, engineering, physics, molecular biology, cardiovascular physiology and imaging scienceswith the goal of collaborating, sharing research and promoting an advanced understanding of the emerging field of cardiovascular molecular imaging.
This meeting continues the work of an earlier initiative held at the National Institutes of Health, which served as the basis for the first textbook dedicated to the field of cardiovascular molecular imaging. The 2009 meeting is designed to stimulate further growth in the field by attracting individuals from both the basic science and clinical communities, with a special emphasis on encouraging participation by junior scientists. The overall structure of the meeting includes a series of lectures by experts in the field, panel discussions and an abstract poster session.
For a complete program, please visit www.snm.org/cvmi2009.
WHO: This program is organized by SNM: Advancing Molecular Imaging and Therapy, with additional support from partners working in molecular imaging and cardiovascular health.
|Contact: Amy Shaw|
Society of Nuclear Medicine